Avenue Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avenue Therapeutics (Nasdaq: ATXI), a specialty pharmaceutical company focusing on neurologic disease treatments, has announced its participation in two upcoming investor conferences. Dr. Alexandra MacLean, the company's CEO, will represent Avenue at these events:

1. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, in New York, featuring a company presentation and one-on-one meetings.

2. Lake Street Capital Markets BIG8 Conference on September 12, 2024, in New York, offering one-on-one meetings.

The H.C. Wainwright presentation will be available for on-demand viewing by conference attendees starting September 9, 2024, at 7:00 a.m. ET. These conferences provide Avenue Therapeutics with opportunities to showcase their progress and engage with potential investors.

MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences:

H.C. Wainwright 26th Annual Global Investment Conference
Date: Monday, September 9, 2024
Location: New York
Format: Company Presentation and 1x1 Meetings

Lake Street Capital Markets BIG8 Conference
Date: Thursday, September 12, 2024
Location: New York
Format: 1x1 Meetings

The H.C. Wainwright company presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET.

About Avenue Therapeutics
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABA_A α2, α3 receptor positive allosteric modulator for CNS diseases, and IV tramadol for the management of acute postoperative pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.

Contact:
Jaclyn Jaffe
Avenue Therapeutics, Inc.
(781) 652-4500
ir@avenuetx.com

FAQ

When is Avenue Therapeutics (ATXI) participating in the H.C. Wainwright Global Investment Conference?

Avenue Therapeutics (ATXI) is participating in the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, in New York.

What is the format of Avenue Therapeutics' (ATXI) participation in the Lake Street Capital Markets BIG8 Conference?

Avenue Therapeutics (ATXI) will participate in one-on-one meetings at the Lake Street Capital Markets BIG8 Conference on Thursday, September 12, 2024, in New York.

Who will represent Avenue Therapeutics (ATXI) at the upcoming investor conferences?

Dr. Alexandra MacLean, Chief Executive Officer of Avenue Therapeutics (ATXI), will represent the company at the upcoming investor conferences.

When will the H.C. Wainwright conference presentation by Avenue Therapeutics (ATXI) be available for viewing?

The H.C. Wainwright conference presentation by Avenue Therapeutics (ATXI) will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET.